Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-65.
周五，强生（NYSE:JNJ）宣布停止评估调查中的二期现场研究，该研究评估了候选抗病毒药物mosnodenvir在年龄在18-65岁之间的成年人中预防登革病毒的疗效。
The decision to discontinue this study is part of a strategic reprioritization of the company's Communicable Diseases research and development (R&D) portfolio. No safety issues were identified.
停止进行这项研究的决定是该公司传染病研究和发展（研发）组合的战略重排序的一部分。没有发现安全问题。
Efficacy data from the Phase 2 field study will be available once the final data analyses, which are now underway, are complete.
二期现场研究的有效性数据将在最终数据分析完成后提供，目前正在进行这项工作。
Also Read: Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug.
另请阅读：强生的Erleada在与辉瑞药物相比的前列腺癌患者中显示出改善的总生存率。
Mosnodenvir (formerly JNJ-1802) was shown to be safe and well tolerated in previous Phase 1 and Phase 2a clinical studies.
以前的一期和二期a临床研究显示，mosnodenvir（原JNJ-1802）的安全性和耐受性良好。
In October 2023, results from the Phase 2a human challenge study found that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo.
2023年10月，二期a人体挑战研究的结果发现，与安慰剂相比，该化合物引起人体对登革病毒（DENV-3）的抗病毒活性。
The study evaluated different dosing regimens – low, medium or high – of JNJ-1802 against an attenuated dengue 3 serotype (DENV-3) in healthy adults.
该研究评估了对健康成年人中的弱化登革热3（DENV-3）采用JNJ-1802的不同剂量方案-低剂量，中剂量或高剂量。
All participants received daily doses of JNJ-1802 or a placebo over 26 days, during which they were challenged with DENV-3 on day 5.
所有参与者在26天内每天接受JNJ-1802或安慰剂的剂量，期间他们在第5天接受了DENV-3的挑战。
All participants were monitored over 85 days. The study found a dose-dependent antiviral effect on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA compared to placebo and was safe and well-tolerated.
所有参与者在85天内接受监测。研究发现与安慰剂相比，存在剂量依赖的抗病毒效果，可减少DENV-3 RNA的可检测性和首次可检测到DENV-3 RNA的时间，并且安全且耐受良好。
In May, Takeda Pharmaceutical Co Ltd's (NYSE:TAK) dengue vaccine received World Health Organization's (WHO) prequalification.
5月，武田制药股份有限公司（纽约证券交易所：TAK）的登革热疫苗获得世界卫生组织（WHO）预认证。
TAK-003 is the second dengue vaccine to be prequalified by WHO.
TAk-003是第二款获得世界卫生组织预认证的登革热疫苗。
WHO recommended using TAK-003 in children aged 6–16 in settings with high dengue burden and transmission intensity.
世卫组织建议在登革热负担和传播强度高的情况下，使用TAk-003疫苗接种6-16岁的儿童。
Price Action: JNJ stock is down 0.60% at $159.53 at the last check on Friday.
股价走势：截至上周五最新检查，强生股价下跌0.60%，报159.53美元。
- Lucid Air Electric Vehicles Join Blink Charging's Envoy Program: Details.
- 露骑士Air新能源车加入blink charging的使者计划：详细信息。
Photo via Shutterstock
图片来自shutterstock。